ArticleMikrochimica acta2026
All-in-one silk-fibroin sustainable high performance electrochemical immunoplatforms: determination of the protein TIM-1 in cancer and allergy scenarios as a case study.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Silk fibroin (SF) is a natural biopolymer extracted from Bombyx mori that has emerged as a promising sustainable material in biosensing applications, especially because of its biodegradable and tunable properties. However, SF is still insufficiently explored in electrochemical biosensing. We present a novel all-in-one electrochemical immunoplatform based on a disposable electrode surface sequentially modified with Prussian Blue (PB) and SF. First, PB is electrodeposited, acting as a redox mediator that enhances signal amplification through its reversible electrochemistry and its low reduction potential for H2O2. The SF layer is here presented as a novel, biocompatible matrix for antibody immobilization that offers structural versatility and sustainability. This dual modification generates a synergistic ecofriendly functional interface that is stable at room temperature. Onto this innovative surface, we have developed a sandwich-type electrochemical immunosensor employing a biotinylated detector antibody and streptavidin–horseradish peroxidase (Strep-HRP) as the enzymatic label for the determination of T-cell immunoglobulin and mucin-domain containing protein 1 (TIM-1, also known as KIM-1 or HAVCR1), a relevant biomarker associated with cancer-related angiogenesis and poor prognosis, and, more recently, with allergenic episodes. The platform enabled sensitive and selective determination of TIM-1 in plasma samples from colorectal cancer (CRC) patients, and saliva samples from individuals undergoing allergic episodes, in which elevated TIM-1 levels were observed. A remarkable advantage of this immunosensor is its operational stability for up to 20 days at room temperature, eliminating the need for a cold chain.
Indexed as
Identifiers
42008197What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.